

2021 Latin America Tumor Markers Market Assessment of 22 Countries-Oncogenes, Bio Markers, GFs, CSFs, Hormones, Stains, LymphokinesCompetitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/267FDD4BC92BEN.html

Date: March 2021

Pages: 580

Price: US\$ 14,500.00 (Single User License)

ID: 267FDD4BC92BEN

Abstracts

This new 22-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

The report is available by section, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale



The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

Oncogenes

Biochemical Markers

Growth Factors

Colony Stimulating Factors

Hormones



Immunohistochemical Stains

Lymphokines

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

Assessment of latest technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies.

Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 580 pages and 72 tables



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
 - 1. Breast Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer



- 5. Stomach Cancer
- 6. Leukemia
- 7. Lymphoma
- 8. Oral Cancer
- 9. Skin Cancer
- 10. Uterine Cancer
- 11. Ovarian Cancer
- 12. Bladder Cancer
- B. Major Current and Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16. NSE
 - 17. Occult Blood
 - 18. PAP Smear/HPV
 - 19. Prostatic Acid Phosphatase (PAP)
 - 20. Prostate-Specific Antigen (PSA)
 - 21. Squamous Cell Carcinoma Antigen (SCC)
 - 22. T and B Lymphocytes
 - 23. TdT
 - 24. Thyroglobulin
 - 25. Tissue Polypeptide Antigen (TPA)
 - 26. Biochemical Tumor Markers
 - 27. Oncogenes

Abl/abl-bcr

AIB1

BCL-2



BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src and others

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains



33. Emerging Tumor Markers

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2



Human Carcinoma Antigen

HPA

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opioid Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL



Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen and others

- C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - 3. Molecular Diagnostics
 - 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. Artificial Intelligence
 - 6. Flow Cytometry
 - 7. Two Dimensional Gel Electrophoresis (2-DGE)
 - 8. Biosensors
 - 9. Competing/Complementing Technologies
- E. Personal Testing

VIII. 22-COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS, SUPPLIER SHARES

IX. COMPETITIVE PROFILES



The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

Abbott

Affymetrix

Beckman Coulter/Danaher

Becton Dickinson

bioMerieux

Bio-Rad

Cepheid

DiaSorin

Eiken Chemical

Elitech Group

Enzo Biochem

Fujirebio

Grifols

Hologic

Leica Biosystems

Ortho-Clinical Diagnostics

PerkinElmer

Qiagen

Roche

Siemens Healthineers

Takara Bio

Thermo Fisher

Wako and others.



List Of Tables

LIST OF TABLES

Argentina Cancer Diagnostic Volume Forecasts by Test Argentina Cancer Diagnostics Sales Forecasts by Test Bolivia Cancer Diagnostic Volume Forecasts by Test Bolivia Cancer Diagnostics Sales Forecasts by Test Brazil Cancer Diagnostic Volume Forecasts by Test Brazil Cancer Diagnostics Sales Forecasts by Test Chile Cancer Diagnostic Volume Forecasts by Test Chile Cancer Diagnostics Sales Forecasts by Test Colombia Cancer Diagnostic Volume Forecasts by Test Colombia Cancer Diagnostics Sales Forecasts by Test Costa Rica Cancer Diagnostic Volume Forecasts by Test Costa Rica Cancer Diagnostics Sales Forecasts by Test Cuba Cancer Diagnostic Volume Forecasts by Test Cuba Cancer Diagnostics Sales Forecasts by Test Dominican Republic Cancer Diagnostic Volume Forecasts by Test Dominican Republic Cancer Diagnostics Sales Forecasts by Test Ecuador Cancer Diagnostic Volume Forecasts by Test Ecuador Cancer Diagnostics Sales Forecasts by Test El Salvador Cancer Diagnostic Volume Forecasts by Test El Salvador Cancer Diagnostics Sales Forecasts by Test Guatemala Cancer Diagnostic Volume Forecasts by Test Guatemala Cancer Diagnostics Sales Forecasts by Test Haiti Cancer Diagnostic Volume Forecasts by Test Haiti Cancer Diagnostics Sales Forecasts by Test Honduras Cancer Diagnostic Volume Forecasts by Test Honduras Cancer Diagnostics Sales Forecasts by Test Jamaica Cancer Diagnostic Volume Forecasts by Test Jamaica Cancer Diagnostics Sales Forecasts by Test Mexico Cancer Diagnostic Volume Forecasts by Test Mexico Cancer Diagnostics Sales Forecasts by Test Nicaragua Cancer Diagnostic Volume Forecasts by Test Nicaragua Cancer Diagnostics Sales Forecasts by Test Panama Cancer Diagnostic Volume Forecasts by Test Panama Cancer Diagnostics Sales Forecasts by Test Paraguay Cancer Diagnostic Volume Forecasts by Test



Paraguay Cancer Diagnostics Sales Forecasts by Test

Peru Cancer Diagnostic Volume Forecasts by Test

Peru Cancer Diagnostics Sales Forecasts by Test

Puerto Rico Cancer Diagnostic Volume Forecasts by Test

Puerto Rico Cancer Diagnostics Sales Forecasts by Test

Uruguay Cancer Diagnostic Volume Forecasts by Test

Uruguay Cancer Diagnostics Sales Forecasts by Test

Venezuela Cancer Diagnostic Volume Forecasts by Test

Venezuela Cancer Diagnostics Sales Forecasts by Test Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications in Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis



I would like to order

Product name: 2021 Latin America Tumor Markers Market Assessment of 22 Countries-Oncogenes, Bio

Markers, GFs, CSFs, Hormones, Stains, Lymphokines-Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and

Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: https://marketpublishers.com/r/267FDD4BC92BEN.html

Price: US\$ 14,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/267FDD4BC92BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$